In MM, saRNAs are being investigated to prolong transient CAR expression in BCMA-targeted CAR-NK cell therapy delivered via lipid nanoparticles, achieving BCMA-specific cytotoxicity in preclinical models of RRMM, and as oncolytic viral vectors (e.g., MV-NIS) in phase I/II trials, leading to complete remission in pretreated RRMM patients (Figure 7), these approaches could synergize with immunotherapies or proteasome inhibitors (e.g., bortezomib) to reduce relapse in RRMM [297,307,363]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.